Skip to main content
Revive Therapeutics Ltd. logo

Revive Therapeutics Ltd. — Investor Relations & Filings

Ticker · RVV ISIN · CA7615161030 LEI · 967600MT7D67TXWXB884 CSE Manufacturing
Open in API
Filings indexed 222 across all filing types
Latest filing 2023-11-06 Regulatory Filings
Country CA Canada
Listing CSE RVV

About Revive Therapeutics Ltd.

https://revivethera.com/

Revive Therapeutics is a life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases and rare disorders. The company's pipeline includes the investigation of Bucillamine for public health medical emergencies and rare inflammatory disorders, alongside the advancement of Psilocybin-based therapeutics. Revive prioritizes leveraging FDA regulatory incentives, such as Orphan Drug and Fast Track designations, to accelerate its drug development programs.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing a new exclusive licensing agreement between Revive Therapeutics and Lawson Health Research Institute to develop and commercialize a novel diagnostic test for long COVID. It contains no financial statements, regulatory filings, or detailed financial performance data. It is a corporate announcement about a business development and research collaboration, not a financial report, earnings release, or regulatory filing. The document length is 8548 characters, which is substantial but the content is clearly a news announcement about a licensing agreement and product development. Therefore, it fits best under the category of Regulatory Filings (RNS) as a general corporate announcement that does not fit other specific categories.
2023-11-06 English
52-109FV1 - Certification of annual filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a FORM 52-109FV1 Certification of Annual Filings Venture Issuer Basic Certificate signed by the CFO of Revive Therapeutics Ltd. It certifies the review and fair presentation of the annual filings for the financial year ended June 30, 2023. The document is a certification letter and does not contain actual financial statements or substantive financial data. It explicitly states it is a certification and notes differences from non-venture issuer certifications. Given the document's nature as an officer certification related to annual filings, it falls under Regulatory Filings (RNS) according to the Certification Rule.
2023-10-28 English
52-109FV1 - Certification of annual filings - CEO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a FORM 52-109FV1 Certification of Annual Filings Venture Issuer Basic Certificate signed by the CEO certifying the accuracy and fair presentation of the annual filings for the financial year ended June 30, 2023. It is a certification letter rather than the actual annual report or financial statements. The document is relatively short (3126 characters) and primarily serves as an officer certification. According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS) rather than the actual annual report (10-K) or other financial reports. Therefore, the correct classification is Regulatory Filings (RNS).
2023-10-28 English
Annual MD&A - English.pdf
Management Reports Classification · 95% confidence The document is titled 'Management’s Discussion and Analysis for the Year Ended June 30, 2023' and contains detailed management commentary on the financial condition, results of operations, forward-looking statements, business summary, and recent developments. It references compliance with National Instrument 51-102 and IFRS standards, and it is dated October 26, 2023. The content is substantive and includes analysis rather than just an announcement or certification. This matches the definition of a Management Reports (MDA) filing, which provides management's detailed explanation of financial results, business trends, and outlook. The document is not an Annual Report (10-K) as it does not contain full financial statements, nor is it a Regulatory Filing (RNS) or Report Publication Announcement (RPA) since it contains detailed discussion and analysis. Therefore, the correct classification is MDA with high confidence.
2023-10-28 English
ON form 13-502F1 (class 1 and 3B reporting issuers - participation fee).PDF
Regulatory Filings Classification · 100% confidence The document is a Form 13-502F1 submission to the Ontario Securities Commission, which is a management certification related to participation fees for Class 1 and Class 3B reporting issuers. It includes detailed calculations of market value of securities and fees payable under OSC Rule 13-502. The document is primarily a certification by an officer (Chief Financial Officer) attesting to the accuracy and completeness of the information provided. There are no financial statements, earnings data, or management discussion of results. The content is regulatory and compliance-related, specifically a certification form submitted to a securities regulator. According to the Certification Rule, documents that are primarily officer certifications or attestations, even if referencing financial data, should be classified as Regulatory Filings (RNS).
2023-10-28 English
Audited annual financial statements – English.pdf
Audit Report / Information Classification · 100% confidence The document is titled 'Independent Auditor's Report' and contains detailed audit opinions, descriptions of audit procedures, and key audit matters related to the consolidated financial statements of Revive Therapeutics Ltd. for the years ended June 30, 2023 and 2022. It includes comprehensive financial statements such as the consolidated statements of financial position, comprehensive loss, and notes to the financial statements. The presence of an auditor's report with an opinion on the financial statements and detailed financial data confirms this is a standalone audit report rather than a full annual report or other filing. The document length (15,000 characters) and content depth indicate it is not a brief announcement or certification. Therefore, the appropriate classification is 'Audit Report / Information' (AR).
2023-10-28 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.